

The background of the slide is a close-up, high-angle shot of numerous round, light blue pills. The pills are densely packed, with some in sharp focus in the foreground and others blurred in the background, creating a sense of depth. The lighting is soft, highlighting the texture of the pills.

PHARMACEUTICAL PROCUREMENT - WHAT IS THE INDUSTRY DOING?

Dr Amy Booth

Nuffield Department of Primary Care Health Sciences
University of Oxford



▲ A woman shows her distress as an inferno nears her home in Gourves, on the Greek island of Evia. The EU yesterday began a huge operation to tackle fires on the island. **Wildfires in Greece** Page 22

Global climate crisis: inevitable, unprecedented and irreversible

● Devastating report is 'code red' warning for 'code red' warning for
Fiona Harvey
Andrew Sparrow
Human activity is changing the

Leader comment
The science is unequivocal. The verdict is clear. There is no more room for manoeuvre.

ever there was going to be a wake-up call to the world when it comes to climate change, this report is it," said Alok Sharma, the minister who will preside over the Cop26 UN climate summit in Glasgow in November. "But the future is not yet written. The very worst of climate change is still avoidable".

FINANCIAL TIMES

UK EIRO Channel Islands E320 Republic of Ireland E320

Silencing staff
NDAs are damaging in the workplace
SARAH O'CONNOR, PAGE 23

In China's debt
African nations' risks in borrow

ely to be 1.5C warmer by 's science panel warns

...rather expected • Call for urgent action



VSPAPER OF THE YEAR + JOURNALISM YO



- Climate change caused by humans is already causing extreme weather in every region across world, with global warming set to breach the 1.5°C target in 2040 – even in best case scenario where world emissions are cut by 60% by 2050
- Climate experts call for Johnson and Sunak to ramp up British climate action, saying the UK is not doing enough to meet the 2050 net-zero target. Lord Stern tells i: 'We need the Prime Minister and Chancellor to take more action now'
- Scientific report most authoritative ever - and backed by 198 governments - says climate change is 'unequivocally' happening
- Severe floods, heatwaves, droughts and storms becoming more frequent and intense



CRISIS

By John Ingham, Environment Editor

A BOMB SHELL. UN reports on global warming is a "wake up call to the world", warns Boris Johnson.

The devastating prediction that heatwaves, flooding and droughts

“Climate change is the biggest global health threat of the 21st century”

THE LANCET

HEALTHCARE

in world's largest economies

4%

of
global emissions

SHIPPING

2-3%

of global emissions

AVIATION

2.4%

of global emissions






+70

health organisations


from +50 countries

On the road to decarbonisation









Pharmaceutical Supply Chain



Pharmaceutical Supply Chain



Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical Companies

by  Amy Booth ^{1,*} ,  Alexandra Jager ¹ ,  Stuart D Faulkner ¹ ,
 Christopher C Winchester ²  and  Sara E Shaw ¹ 



Sampling:

- Largest 20 pharmaceutical companies by revenue

- | | |
|-------------------------------|-------------------------------|
| 1. Roche | 11. AstraZeneca |
| 2. Novartis | 12. Amgen |
| 3. AbbVie | 13. Gilead Sciences |
| 4. Johnson and Johnson (J&J) | 14. Eli Lilly |
| 5. Bristol Myers Squibb (BMS) | 15. Novo Nordisk (NN) |
| 6. Merck & Co./MSD | 16. Bayer |
| 7. Sanofi | 17. Boehringer Ingelheim (BI) |
| 8. Pfizer | 18. Astellas Pharma |
| 9. GlaxoSmithKline (GSK) | 19. Viatris |
| 10. Takeda | 20. Teva Pharmaceuticals |



Data collection:

- Sustainability tabs
- 2020/2021 Company Reports



Content analysis:

- Climate change targets
- Reported GHG emissions
- Emission reduction strategies

GHG Emissions



SCOPE 1

Emissions from owned sources



SCOPE 2

Indirect energy emissions



SCOPE 3

Other indirect emissions

Climate Targets



Science Based Targets initiative



Net Zero Standard (April 2023)

1. Near-term target

$$\begin{aligned} \text{Absolute reduction target} \\ \text{Scope 1, 2} &= \begin{cases} \text{Base year} \leq 2020, & 4.2\% \times (\text{Target year} - \text{Base year}) \\ \text{Base year} > 2020, & 4.2\% \times (\text{Target year} - 2020) \end{cases} \\ \text{Absolute reduction target} \\ \text{Scope 3} &= \begin{cases} \text{Base year} \leq 2020, & 2.5\% \times (\text{Target year} - \text{Base year}) \\ \text{Base year} > 2020, & 2.5\% \times (\text{Target year} - 2020) \end{cases} \end{aligned}$$

2. Long-term target

a) Reduce scope 1, 2, and 3 emissions to zero or a residual level consistent with reaching net zero emissions (90%) with neutralisation of remaining emissions (10%), by 2050 or earlier.

Company Targets

1. Do they have targets?
2. Do their targets cover all scopes (check footnotes!)?
3. Are their targets aligned with a 1.5°C scenario (or at least 2°C)?

*Checked 01/06/2023

Only long-term target included where companies reported both near- and long-term

2027

CARBON NEUTRAL

Amgen (1, 2)

2030

NET ZERO

Gilead (1, 2)

2030

CARBON NEUTRAL

Johnson & Johnson (1, 2) Eli Lilly (1, 2)
Boehringer Ingelheim (1, 2)

2040

NET ZERO

Novartis (1, 2, 3) Pfizer (1, 2, 3) Takeda (1, 2, 3)

2040

CARBON NEUTRAL

BMS (1, 2) Merck & Co (1, 2)

2045

NET ZERO

Sanofi (1, 2, 3) GSK (1, 2, 3)
AstraZeneca (1, 2, 3) Novo Nordisk (1, 2, 3)

2030

ABSOLUTE REDUCTION


Teva (1, 2: -46%; 3: -25%) Viatris (1, 2: -42%; 3: -25%) Merck & Co (3: -52%)
Johnson & Johnson (3: -16%)

2050


NET ZERO

Roche (1+2) AbbVie (1, 2, 3) Bayer (1, 2, 3)
Astellas (1, 2, 3)

Company Emissions



Company Strategies



🕒 20 September 2021


GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero 'breakthrough' at UN Climate Week



RE100

EV100

EP100



Considerations for Procurers

1. Does the company report on ALL its GHG emissions?
2. Does the company use globally accepted guidelines to report GHG emissions e.g., GHG Protocol?
3. Has the company been able to demonstrate any reductions in GHG emissions?
 - a) Remember to check the baseline year.
 - b) Consider the baseline GHG emissions.
 - c) Consider the company's operations and the external context.
4. Do they have targets that cover all scopes and are aligned with a 1.5°C scenario (or at least 2°C)?
5. Do they have a detailed plan outlining how they plan to reach their target and reduce their emissions?



UN
DP

Empowered lives.
Resilient nations.



Global

Make a D

NET-ZERO SUPPLIER ROADMAP

'Taking Account of Carbon Reduction Plans'

All suppliers with new contracts over £5m per annum will publish a carbon reduction plan for direct emissions.

Direct and Indirect Emissions

All suppliers will produce a carbon reduction plan that takes into account the suppliers' direct and indirect emissions.

New Requirements

Requirements will be introduced overseeing the provision of carbon foot-printing for individual products supplied to the NHS.

Supplier Framework

Suppliers will only qualify for NHS contracts if they can demonstrate their progress through published progress reports and carbon emissions reporting through the supplier framework.

2023

2027

2028

2030



Europe
Commi

Environment

Home > Green Public Procurement

[Green Public Procurement](#)

[News and Events](#)

Sustainable Health Procurement Guidance Note



ABOUT TOPICS RESOURCES DATA AND AWARDS

SUSTAINABLE PROCUREMENT GUIDE

WHAT OTHER CRITERIA?

Pharmaceuticals and Environment

Here you can find information about the environmental impact of pharmaceuticals. You can search for a substance name. The environmental risk refers to the use of a pharmaceutical. The knowledge support is based on three sources:

1. environmental information from the European Medicines Agency's (EMA's) European Public Assessment Reports (EPARs)
2. environmental information on Fass.se
3. environmental risk assessments for certain substances based on concentrations measured in the environment in Sweden and effect studies.



MCF
CLASSIFIER

bsi.

CONCLUSIONS

- Climate change solutions require input from all parties, including health systems.
- The pharmaceutical industry is taking up the fight; there is room for further action, novel solutions and collaborations to advance this agenda.
- There is a role for sustainable procurement to motivate upstream action and downstream sustainable prescribing; but more work needs to be done to develop procurement criteria and access data.

THANKYOU



Amy Booth
University of Oxford



amy.booth@gtc.ox.ac.uk

